The incidence of vincristine-induced acute neuropathy has been noted to be as high as 100% in children, while severe peripheral neuropathy occurs in approximately 10% of the children with cancer (Kandula et al., 2016) . Most CIPN resolves within 3 months after completion of chemotherapy; however, some symptoms may persist, especially symptoms caused by vincristine (Loprinzi, 2017) .
Monitoring and accurately reporting side effects during clinical trials of treatment regimens for cancer is vital. There are a variety of peripheral neuropathy assessment tools currently in use, but the accuracy of these tools in identifying neuropathy in children varies. Young children with limited vocabulary may be unable to describe the sensations or deficits that are associated with peripheral neuropathy. Reliable tools must be identified and used when evaluating neuropathy in children during and after they receive chemotherapy. Currently, there is not one consistently used tool to measure CIPN in children with cancer. Therefore, a systematic review was performed to describe the reliability of CIPN assessment tools for children receiving vincristine.
A PICOT question was developed to focus the systematic review. PICOT represents Patient, Intervention or Issue of Interest, Comparison, Outcome, and Time (Melnyk & Fineout-Overholt, 2015) . The following PICOT question was used to guide this review: "In pediatric patients receiving vincristine, what assessment tools best evaluate early onset and progression of peripheral neuropathy?"
Systematic Review Methods
An evidence-based practice (EBP) project proposal was submitted and approved by the Children's Oncology Group (COG) Nursing Discipline under the COG Nursing Evidence-Based Practice initiative. This initiative is designed to address clinical issues not typically broached in protocols but pertinent to the nursing care of patients throughout therapy. The evidence-based review team consisted of a pediatric nurse practitioner, physician assistant, physical therapist, orthopedic surgical registered nurse, and 2 research oncology registered nurses. A doctorally prepared nurse researcher from the COG Nursing Discipline served as the project mentor.
A medical librarian and research assistant conducted the electronic search of 4 databases, including PubMed, CINAHL, Cochrane, and the National Guidelines Clearinghouse. Key terms guiding the search were peripheral neuropathy, pediatric, and assessment. Vincristine and oncology were not included as key terms to obtain all available evidence focused on pediatric peripheral neuropathy assessment. Due to the limited literature related to pediatric patients with cancer with peripheral neuropathy, the search was expanded to all pediatric diseases. All published years were included in the literature search with English used as the only limit. The original search yielded 182 articles, with 2 additional articles located by hand searching, which were duplicates (Figure 1) . No clinical guidelines relevant to the PICOT question were identified. The team reviewed all 182 abstracts to determine if the articles met the inclusion criteria. The inclusion criteria consisted of research-based articles that included an evaluation of a peripheral neuropathy assessment tool with participants aged 1 to 18 years. After excluding articles that did not meet the inclusion criteria, the number of available articles for use as evidence sources was reduced to 8. Five articles were focused on children with cancer, and 3 articles were focused on children with type 1 diabetes.
Matrix tables (Garrard, 2014) were used to extract key information and to summarize the following components of each article: purpose, design, variables, settings/subjects, measurement and instruments, and results/implications. In addition, the quality of each article was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria (Guyatt et al., 2011) and issues with methodological flaws, inconsistencies, indirectness, imprecision, and publication bias were noted on the matrix tables. The matrix table for each article was completed by 1 team member, who then presented the information to the group via a monthly Loprinzi (2017) and Biedrzycki (2015) .
conference call, where the summary and quality issues were reviewed and agreed upon by group consensus.
Evidence Review

Peripheral Neuropathy Assessment Tools
Ten pediatric peripheral neuropathy assessment tools were identified from the evidence. Three instruments, the Common Terminology Criteria for Adverse Events (CTCAEv3.0/v4.0), the pediatric-modified Total Neuropathy Scale (ped-m TNS), and the Total Neuropathy Scale-Pediatric Version (TNS-PV), include subjective and objective assessments to evaluate the presence and extent of peripheral neuropathy. One instrument, the Wong-Baker FACES pain scale, is a subjective report of current pain perceptions conveyed on a Likert-type scale. The remaining 5 assessment tools, nerve conduction study, neurological exam, current perception threshold (CPT), tactile perception threshold (TPT), and vibration perception threshold (VPT) are objective evaluations of peripheral neuropathy determined by physical assessments. These tools are described further in Table 2 .
Peripheral Neuropathy Assessment Tool Evidence
A total of 8 studies are included in the evidence synthesis. Three studies evaluated the ped-m TNS tool among pediatric patients with cancer, 2 studies evaluated the TNS-PV tool among pediatric patients with cancer, and the remaining 3 studies evaluated neurological assessments among pediatric patients with diabetes (Table 3) .
The ped-m TNS is a peripheral neuropathy assessment tool that includes both symptom assessment and physical evaluation. Gilchrist, Tanner and Hooke (2009) implemented a feasibility test among 20 pediatric patients with cancer and demonstrated that all patients aged 5 to 18 years were able to complete the ped-m TNS assessment. Results indicated that sensory symptoms (feelings of tingling, numbness, or pain) did not correlate with pin sensitivity (p = .549) or vibration sensibility (p = .595). However, motor symptoms (difficulty buttoning shirts or tying shoes, difficulty walking or going up stairs, and difficulty extending arm over his or her head) moderately correlated with strength (r s = 0.544, p = .011), deep tendon reflexes (r s = 0.456, p = .043), and vibration (r s = 0.613, p = .004). Gilchrist and Tanner (2013) further investigated the validity of the ped-m TNS with a group of 41 children aged 5 to 18 years old. There was a negative association with the ped-m TNS score and balance (r s = −0.626, p < .001) and manual dexterity (r s = −0.461, p < .001) such that higher scores on the tool indicated worse balance and manual dexterity. Interestingly, there was no correlation `found between the cumulative vincristine dose and the ped-m TNS score. Using the sample from the previous study, Gilchrist, Marais, and Tanner (2014) extended the findings by comparing the ped-m TNS with the CTCAEv3.0. There was no correlation noted between the ped-m TNS scores and the combined sensory and motor CTCAEv3.0 scores. Most participants with some degree of neuropathy (84%, n = 16) were missed by the CTCAEv3.0 scoring. There was no correlation between the sensory symptom scores on the ped-m TNS and the sensory scores on the CTCAEv3.0, and no correlation between motor symptoms on the ped-m TNS and motor scores on the CTCAEv3.0; however, there was moderate association between strength testing on the ped-m TNS and the motor portion of the CTCAEv3.0 (r s = 0.43, P < .01).
Lavoie Smith and colleagues (2013) developed 2 versions of the TNS-PV scale: an original version (version A) to evaluate lower or upper extremity symptoms and an alternative version (version B) to score lower and upper extremity symptoms by a trained evaluator. An item analysis showed no statistical difference between versions A and B. Among the 7 items on the TNS-PV, tendon reflexes and vibration were the most responsive items, which correlated closely to the overall TNS-PV scores (effect size = 0.65, P < .0001). It is important to note that some items on the scale were difficult to obtain in young children. Vibration and temperature could not be measured in 87% of the children ≤3 years old and numbness, paresthesia, and neuropathic pain could not be measured in 48% of 3-year-old children; however, 91% of all children were cooperative for the reflex testing, and 78% of all children participated in the strength testing. All the items on the TNS-PV were attainable in children ≥6 years old.
When evaluating vincristine cumulative dose and neuropathy assessment scores in children, the TNS-PV more closely correlated with the cumulative dosage (r = 0.53, P = .01) than the CTCAEv4.0 sensory measure (r = 0.31, P = .05) and the CTCAEv3.0 motor measure (nonsignificant) (Lavoie Smith et al., 2013) . The TNS-PV identified more children with vincristine-induced peripheral neuropathy than the CTCAEv4.0 (Lavoie Smith et al., 2015) .
Subjective symptoms alone on the TNS-PV were unreliable for detecting peripheral neuropathy. An evaluation of 1539 assessments among 128 children receiving vincristine found that 44% of children reported pain on the subjective symptom item, but 78% had peripheral neuropathy (Lavoie Smith et al., 2013) . Furthermore, children's ratings on the FACES pain scale demonstrated only a weak correlation with the TNS-PV scale (r = 0.38, P = .01).
Two studies assessed children with type 1 diabetes and demonstrated a low sensitivity in diagnosing peripheral neuropathy when using a clinical examination compared with nerve conduction studies (Holiner et al., 2013; Nelson et al., 2006) . Out of 73 children with type 1 diabetes, 42 (57%) were diagnosed with neuropathy by using nerve conduction studies, but only 26 (36%) had an abnormal neurological exam (Nelson et al., 2006) . Another study of 39 children with type 1 diabetes identified 15 children (38%) with abnormal nerve conduction No correlation with cumulative dose vincristine and neuropathy score or with cumulative vincristine dose and balance and manual dexterity Cancer patients had worse ped-m TNS scores (2-18) than controls (0-4) Neuropathy measures found negative associations with balance (r s = −0.626, P < .001) and manual dexterity (r s = −0.461, P < .001) Gilchrist, 2014 Descriptive, 60 oncology patients aged 5-18 years ped-m TNS, CTCAEv3.0 Median ped-m TNS score 9, range 2-19 Median CTCAE sensory score 0, range 0-3 Median CTCAE motor score 2, range 0-3 No patients received score of 0 on ped-m TNS; one-third of participants received 0 score on CTCAE version 3.0 No correlation between ped-m TNS and combined sensory/motor CTCAE scores (P = .07) Sensitivity of CTCAE sensory score 0.2, specificity 0.8 Sensitivity of CTCAE motor score 0.7, specificity 1.0 Lavoie Smith, 2013 Descriptive, 65 children with leukemia TNS-PV, CTCAEv4.0, Balis Pediatric Scale of Peripheral Neuropathies, Tuning fork, FACES Responsiveness to change over time: Reflex, temperature, and vibration items most responsive (effect size = 0.31-0.66, P = .006 to <.0001) TNS-PV version A correlation with CTC and Balis scores (r = 0.48-0.52, P = .01) TNS-PV not highly correlated with FACES (r = 0.20, P = .01). Lavoie Smith, 2015 Descriptive, 109 children with leukemia studies, but only 6 of these children had clinical evidence of peripheral neuropathy using neuropathy symptom scores or neuropathy disability scores; 9 of the children were asymptomatic (Holiner et al., 2013) . While specificity of peripheral neuropathy using the neurological exam was high in both studies (81% and 100%), sensitivity or probability of detection of peripheral neuropathy using the neurological exam remained low (48% and 40%) (Holiner et al., 2013; Nelson et al., 2006) . Perception threshold is another method to identify peripheral neuropathy and evaluates detection of the lowest level of vibration and/or tactile stimulation. A total of 73 children with diabetes were evaluated for peripheral neuropathy using the perception threshold and found to have low sensitivity and specificity of the VPT (62% and 65%) and the TPT (19% and 64%; Nelson et al., 2006) . The authors concluded that both VPT and TPT should not be used as a screening tool for peripheral neuropathy in children (Nelson et al., 2006) .
Another perception threshold tool is the CPT, a noninvasive measurement of peripheral neuropathy that uses a neurometer to determine at what amplitude the patient can detect a buzzing or tingling sensation (Lv et al., 2015) . A study of 52 patients with diabetes and 40 matched healthy controls found significantly lower CPTs at 2000, 250, and 5 Hz among the patients with diabetes when compared with healthy controls (P = .001-.009; Lv et al., 2015) . Thus, CPT appears to provide early detection of peripheral neuropathy.
Appraisal of the Quality of Evidence
The quality of the peripheral neuropathy assessment tool evidence is based on 8 research articles. The majority of these studies consisted of descriptive designs. Small sample sizes were of concern related to the methodology of the evidence, but no other methodological flaws were identified. There were no issues with inconsistency, indirectness, imprecision, or publication bias. The overall rating of the quality of the body of evidence is low quality.
Recommendations
1. There is a strong recommendation that all pediatric patients receiving vincristine should receive a formal assessment for peripheral neuropathy. 2. There is a strong recommendation that the ped-m TNS or TNS-PV should be used for the assessment of vincristine-induced peripheral neuropathy in children ≥6 years old. 3. There is a strong recommendation against the use of subjective symptoms alone to assess for peripheral neuropathy in children receiving vincristine.
Discussion
Despite the importance of assessment of peripheral neuropathy, a reliable and valid assessment tool specific to pediatric patients is not widely used. Through this systematic review, the CTCAEv3.0 was found to underreport peripheral neuropathy, especially in the pediatric population, and the tool missed most participants who had some degree of neuropathy (Gilchrist et al., 2014) . These findings suggest that the CTCAEv3.0 may not be an appropriate assessment tool for identifying peripheral neuropathy in pediatric patients. Two assessment tools for peripheral neuropathyped-m TNS and TNS-PV-show promise for evaluating peripheral neuropathy in children; however, additional research is necessary to determine the usability and reliability in children younger than 6 years. CPT has also demonstrated promise in identifying peripheral neuropathy in adolescents and young adults, but further research is needed to determine if neuropathy can be identified with this tool in younger children and in patients receiving vincristine.
Findings regarding the relationship between cumulative dosing of vincristine and severity of peripheral neuropathy have been found to differ between the studies using ped-m TNS and TNS-PV. Lavoie Smith and colleagues 2013 found that cumulative vincristine dose was related to worse peripheral neuropathy using the TNS-PV tool. This is in contrast to Gilchrist and colleagues 2013, who found no relation between cumulative vincristine dose and severity of peripheral neuropathy using the ped-m TNS. Additional research is necessary to determine whether the cumulative dose of vincristine has an impact on severity of CIPN. Determining if cumulative dosing correlates with worsening peripheral neuropathy will guide timing and frequency of assessments and interventions.
Because vincristine is a mainstay pediatric chemotherapeutic agent known to cause peripheral neuropathy, it is essential that pediatric oncology health care providers are well versed in the assessment of peripheral neuropathy signs and symptoms. Nurses are commonly on the front line of patient care in both inpatient and outpatient settings, where children are receiving vincristine and other chemotherapeutic agents that may cause peripheral neuropathy. Nursing assessment of peripheral neuropathy should be integral and standard assessment in patient care throughout the course of treatment. Peripheral neuropathy assessment must go beyond solely asking subjective symptom questions and expand to the use objective measures to evaluate peripheral neuropathy. Underreporting of peripheral neuropathy has been found when using subjective assessment alone, causing some patients with peripheral neuropathy to go undiagnosed (Lavoie Smith et al., 2013) . Detecting peripheral neuropathy early, and effectively addressing signs and symptoms that cause pain, discomfort, and functional decline, has the potential to improve health-related quality of life in children undergoing cancer treatment.
